Omaveloxolone

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 135 publications

Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension.

Omaveloxolone Driven NRF2 Activation as a Novel Therapeutic Strategy for Pulmonary Hypertension.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: July 27, 2026

Unlocking Sulforaphane's Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons.

Unlocking Sulforaphane's Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons.

Journal: Antioxidants & redox signaling

Published: July 20, 2026

Predicting disease progression in progressive cerebellar ataxias: integrating clinical, imaging, fluid, genetic, and digital biomarkers.

Predicting disease progression in progressive cerebellar ataxias: integrating clinical, imaging, fluid, genetic, and digital biomarkers.

Journal: Frontiers in neurology

Published: June 27, 2026

Pharmacological treatments for Friedreich ataxia.

Pharmacological treatments for Friedreich ataxia.

Journal: The Cochrane database of systematic reviews

Published: May 12, 2026

Evolution of Friedreich's Ataxia Management Across Established and Emerging Therapies-Systematic Review and Meta-Analysis.

Evolution of Friedreich's Ataxia Management Across Established and Emerging Therapies-Systematic Review and Meta-Analysis.

Journal: Journal of clinical medicine

Published: May 09, 2026

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models.

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models.

Journal: Frontiers in pharmacology

Published: May 04, 2026

RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells.

RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells.

Journal: Hepatic oncology

Published: April 27, 2026

Slowing the curve: a single-arm meta-analysis of mFARS outcomes following omaveloxolone treatment in Friedreich ataxia.

Slowing the curve: a single-arm meta-analysis of mFARS outcomes following omaveloxolone treatment in Friedreich ataxia.

Journal: BMJ neurology open

Published: April 07, 2026

Inhibition of smooth muscle phenotypic modulation by bardoxolone methyl, omaveloxolone, and cinnamaldehyde is Nrf-2 dependent.

Inhibition of smooth muscle phenotypic modulation by bardoxolone methyl, omaveloxolone, and cinnamaldehyde is Nrf-2 dependent.

Journal: Advances in redox research

Published: March 27, 2026

Multitarget therapeutic potential of sulforaphane in ethidium bromide-induced neurotoxicity in multiple sclerosis-like pathology: comparison with omaveloxolone and dimethyl fumarate on neuroprotection and systemic recovery.

Multitarget therapeutic potential of sulforaphane in ethidium bromide-induced neurotoxicity in multiple sclerosis-like pathology: comparison with omaveloxolone and dimethyl fumarate on neuroprotection and systemic recovery.

Journal: Scientific reports

Published: March 25, 2026

Metal-dependent regulated cell death: Molecular architecture and translational frontiers.

Metal-dependent regulated cell death: Molecular architecture and translational frontiers.

Journal: iMeta

Published: March 16, 2026

Application of a Blood-Brain Barrier Organ-on-a-Chip Model for Assessment of Countermeasure Efficiency Against Eastern Equine Encephalitis Virus.

Application of a Blood-Brain Barrier Organ-on-a-Chip Model for Assessment of Countermeasure Efficiency Against Eastern Equine Encephalitis Virus.

Journal: Viruses

Published: February 26, 2026

Showing 1-12 of 135

Last Updated: 09/26/2026